Report Category

Pharmaceutical Market Research Reports

In-depth market intelligence covering drug development, CDMO outsourcing, API manufacturing, biosimilars, oncology, cell & gene therapy, clinical trials, and specialty pharma — with 10-year forecasts, 15–25 KOL interviews per report, and competitive landscape analysis.

340+
Reports
10yr
Forecasts
15–25
KOL Interviews

Pharmaceutical Industry Market Intelligence

The global pharmaceutical market continues to evolve rapidly, driven by the acceleration of biologics and biosimilar development, the expansion of CDMO outsourcing models, advances in cell and gene therapy manufacturing, and the growing demand for complex drug delivery systems. InsightAce Analytic's pharmaceutical report library covers the full value chain — from active pharmaceutical ingredient sourcing and continuous manufacturing to clinical trial logistics and post-market commercialization.

CDMO & Contract ManufacturingOutsourcing models, capacity analysis, competitive positioning
API & Drug SubstanceSupply chain, HPAPI, peptide APIs, oligonucleotides
Oncology & Immuno-OncologyADCs, bispecifics, CAR-T, radiopharmaceuticals
Drug Delivery SystemsLNP platforms, nasal, transdermal, implantable devices
Biosimilars & BiologicsPatent cliffs, pipeline analysis, market penetration
Cell & Gene TherapyManufacturing, logistics, vein-to-vein supply chain
Clinical Trials & CRODecentralized trials, site management, real-world evidence
Rare Diseases & Orphan DrugsRegulatory pathways, pricing, competitive dynamics
CNS & NeurologyNeurodegeneration, psychiatric, digital therapeutics

Genome Editing/Genome Engineering Market Size, Share & Trends Analysis Report By Technology (CRISPR, TALEN, ZFN, Antisense, and Other Technologies), By Products, By Application, By End Users, Region And Segment Forecasts, 2023-2031.

The Genome Editing/Genome Engineering Market Size is valued at 5900.0 Million in 2022 and is predicted to reach 28469.3 Million by the year 2031 at a 19.20 % CAGR during the forecast period for 2023-2031. Genome engineering is the technique that involves gene modification by certain process include DNA is insertion, cutting, modification or replacement of genome of a living organism. Due to increasing the research and development spend by comp...

ID: 1174 180 Pages March 2024

Alpha 1 Lung Disease Market Size, Share & Trends Analysis Report By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, Others), By Treatment Type (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others), By Route of Administration, By Distribution Channel, By End User, By Region, And By Segment Forecasts, 2023-2031.

Alpha 1 Lung Disease Market Size is valued at USD 4.13 Billion in 2022 and is predicted to reach USD 19.93 Billion by the year 2031 at a 19.33% CAGR during the forecast period for 2023-2031. Alpha-1 Antitrypsin Deficiency is a genetic disorder in which the body does not make enough of a protein known as alpha-1 antitrypsin. This protein is very important for keeping the lungs safe from damage caused by inflammation. People who don't get enough...

ID: 2274 180 Pages March 2024

Nucleic Acid Sample Preparation Market Size, Share & Trends Analysis Report By Product (Consumables (Kits (DNA/RNA Sample Isolation/Extraction/Purification, DNA/RNA Clean-Up and Concentration, DNA and RNA Quantification), Reagents), Instruments), By Technology (Silica-Based, Magnetic Particle Technology), By Source Type, By Application, By End-user, By Region, And By Segment Forecasts, 2024-2031

Nucleic Acid Sample Preparation Market Size is valued at USD 2.89 Billion in 2023 and is predicted to reach USD 4.57 Billion by the year 2031 at a 6.10% CAGR during the forecast period for 2024-2031. Molecular biology relies on nucleic acid sample preparation to extract, purify, and concentrate DNA or RNA from blood, tissue, cell, and environmental samples. High-quality nucleic acids are essential for genetic and molecular analysis like PCR, N...

ID: 2386 180 Pages March 2024

Swab And Viral Transport Medium Market Size, Share & Trends Analysis Report By Product (Swab Type (Nasal Swabs, Nasopharyngeal Swabs and Throat Swabs), Transport Medium), By Application, By End-User, By Region, And By Segment Forecasts, 2024-2031

The Swab And Viral Transport Medium Market Size is valued at 8.09 Billion in 2023 and is predicted to reach 13.16 Billion by the year 2031 at a 6.47 % CAGR during the forecast period for 2024-2031. Viral transport medium is used to collect, transport, maintain and store the clinical specimens containing viruses, chlamydia, mycoplasma or ureaplasma organisms. A viral skin swab is lightly rubbed against a visible skin lesion or vesicle and ...

ID: 1125 180 Pages March 2024

Combo IVD Market Size, Share & Trends Analysis Report By Test Type (SARS-CoV-2 Flu A/B Combo Test, COVID-19, Influenza A/B, RSV Combo test, COVID-19 IgM/IgG Combo Test, HIV-1/2 Ag/Ab Combo Test, HIV/Syphilis Ab Combo Test, HIV, HBsAg, HCV & Syphilis Combo, hCG Combo Test, Thrombophilia Detection Combo Test, Other Test Types), By Testing, By End-User, By Channel, By Sample Type, By Region, And By Segment Forecasts, 2024-2031

Combo IVD Market Size is valued at USD 550.12 Mn in 2023 and is predicted to reach USD 920.86 Mn by the year 2031 at a 6.84% CAGR during the forecast period for 2024-2031. Combo in vitro diagnostics (IVDs) refers to medical tools that measure and analyze biological samples in a controlled environment. These tests are useful for detecting and monitoring a wide range of medical illnesses, including infectious disorders and autoimmune diseases. T...

ID: 2376 180 Pages March 2024

Coagulation Factor Deficiency Market Size, Share & Trends Analysis Report By Deficiency Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, and Others), By Product Type, By End Users, By Region, And By Segment Forecasts, 2024-2031

Coagulation Factor Deficiency Market Size is valued at USD 5.50 Bn in 2023 and is predicted to reach USD 9.60 Bn by the year 2031 at a 7.36% CAGR during the forecast period for 2024-2031.  Coagulation factor deficiency refers to a medical disorder characterized by an inadequate or malfunctioning of coagulation factors, which are proteins responsible for blood clotting. This can result in hemorrhagic diseases, manifesting as signs suc...

ID: 2163 180 Pages March 2024

Chapel Disease Therapeutics Market Size, Share & Trends Analysis Report By Type (Eculizumab, Ravulizumab, Veopoz), By Diagnosis (Gastrointestinal Symptoms, Edema, Hypoalbuminemia, Hypogammaglobulinemia, Malnutrition), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region, And By Segment Forecasts, 2024-2031

Chapel Disease Therapeutics Market Size is valued at USD 144.89 Mn in 2023 and is predicted to reach USD 161.10 Mn by the year 2031 at a 1.41% CAGR during the forecast period for 2024-2031. Chapel Syndrome is a rare genetic condition affecting the immune system. CHAPLE stands for "CD55 deficiency, hyperactivation, angiopathic thrombosis, and severe protein-losing enteropathy (PLE)." Chaple is characterized by severe protein-losing enteropathy,...

ID: 2360 180 Pages March 2024

Omics-Based Clinical Trials Market Size, Share & Trends Analysis Report By Phase Type (Phase I, Phase II, Phase III, and Phase IV), By Study Design Type (Interventional Studies, Observational Studies, and Expanded Access Studies), By Indication Type (Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases, and Others), By Region, And By Segment Forecasts, 2024-2031

Omics-Based Clinical Trials Market Size is valued at USD 29.51 billion in 2023 and is predicted to reach USD 54.42 billion by the year 2031 at a 8.13% CAGR during the forecast period for 2023-2031. Omics-based clinical trials represent a significant shift towards more precise and personalized healthcare, offering the promise of better-targeted therapies with higher efficacy and fewer side effects. As the field evolves, continued advancements i...

ID: 2355 180 Pages March 2024

Autoimmune Polyglandular Syndrome Type 1 Market Size, Share & Trends Analysis Report By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Age of Onset (Childhood, Adult, Adolescent), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration, End-Users, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031

Autoimmune Polyglandular Syndrome Type 1 Market Size is valued at USD 244.1 Mn in 2023 and is predicted to reach USD 389.6 Mn by the year 2031 at a 6.20% CAGR during the forecast period for 2024-2031. Autoimmune Polyglandular Syndrome type 1 is an uncommon autosomal recessive disorder characterized by hypoparathyroidism, adrenal insufficiency, and chronic mucocutaneous candidiasis. These are its three main manifestations. APS-1 does, nonethele...

ID: 2357 180 Pages March 2024

DNA/RNA Sample Extraction and Isolation Market Size, Share & Trends Analysis Report By Product (Consumables (Kits (DNA Kits, RNA Kits), Reagents), Instruments), By Technology (Consumable-Based Technology (Silica-Based, Magnetic Particle Technology, Other Technologies), Instrument-Based Technology (Automated Spin Column-Based, Magnetic Bead-Based, Automated Liquid Handling), By Application, By End-User, By Region, And By Segment Forecasts, 2024-2031

DNA/RNA Sample Extraction and Isolation Market Size is valued at USD 2.47 Bn in 2023 and is predicted to reach USD 4.14 Bn by the year 2031 at a 6.80% CAGR during the forecast period for 2024-2031.  The extraction and isolation of DNA/RNA samples are critical operations in molecular biology and genetics research. They involve the extraction of nucleic acids (DNA and RNA) from cells, tissues, or biological fluids for use in PCR, seque...

ID: 2199 180 Pages March 2024

Key Pharmaceutical Sub-Segments We Cover

CDMO & Contract Manufacturing

The pharmaceutical CDMO market is expanding rapidly as drug developers increasingly outsource manufacturing to reduce capital expenditure and accelerate time-to-market. Our CDMO reports cover small molecule contract manufacturing, biologics CDMO, fill-finish services, and continuous manufacturing outsourcing with competitive landscape analysis of leading CDMOs worldwide.

API & Drug Substance Manufacturing

Active pharmaceutical ingredient sourcing and manufacturing is a critical strategic decision for pharma companies. Our API reports analyze supply chain dynamics, pricing trends, geographic manufacturing shifts, and the growing demand for high-potency APIs, peptide APIs, and oligonucleotide synthesis.

Drug Delivery Systems

Innovation in drug delivery — from nasal and transdermal systems to lipid nanoparticle platforms and controlled-release formulations — is reshaping how therapeutics reach patients. We cover the full spectrum of delivery technologies including inhalation devices, implantable systems, and targeted nanoparticle carriers.

Oncology & Immuno-Oncology

Oncology remains the largest therapeutic area by R&D investment. Our reports cover bispecific antibodies, antibody-drug conjugates, checkpoint inhibitors, CAR-T therapies, radiopharmaceuticals, and companion diagnostics with pipeline analysis and competitive positioning.

Biosimilars & Biologics

The biosimilar market is driven by patent cliffs of blockbuster biologics and increasing regulatory clarity. We analyze biosimilar development pipelines, interchangeability trends, market penetration dynamics, and the competitive strategies of both originator and biosimilar manufacturers.

Why Choose InsightAce for Pharmaceutical Market Intelligence?

  • Original primary research — 15–25 KOL interviews per report with pharma executives, CDMO leaders, formulators, and regulatory experts
  • 10-year market forecasts — analyst-built models with top-down and bottom-up triangulation, covering 2026–2035
  • Competitive landscape — detailed profiling of 15–25 companies per report including revenue analysis, pipeline mapping, and strategic positioning
  • Segmentation depth — by type, application, technology, formulation, route of administration, end-user, and region
  • Post-purchase support — dedicated analyst hours for follow-up questions, custom data tables, and presentation-ready slides

Frequently Asked Questions

How many pharmaceutical market research reports does InsightAce publish?

InsightAce Analytic has published 340+ pharmaceutical market research reports covering drug development, CDMO outsourcing, API manufacturing, biosimilars, clinical trials, and specialty pharma with 10-year forecasts.

What pharmaceutical sub-segments does InsightAce cover?

We cover CDMO & contract manufacturing, API & drug substance, drug delivery systems, oncology & immuno-oncology, biosimilars & biologics, cell & gene therapy, rare diseases & orphan drugs, CNS & neurology, and clinical trials & CRO markets.

What is included in InsightAce pharmaceutical reports?

Each report includes 10-year market size forecasts, competitive landscape with 15-25 company profiles, segmentation by type, application, and region, 15-25 KOL interviews, and post-purchase analyst support.

Can I customize a pharmaceutical report?

Yes. Every report purchase includes free 10% customization. You can add countries, extend the forecast period, add company profiles, or request specific segmentation cuts.

How do I request a sample pharmaceutical report?

Click "Request Sample" on any report card to receive an executive summary, table of contents, and sample data tables delivered to your email.